Cell-substrate impedance monitoring of cancer cells

Patent metadata

Field	Value
Publication number	US-12066428-B2
Application number	US-202017083589-A
Country	US
Kind code	B2
Filing date	Oct 29, 2020
Priority date	Nov 20, 2015
Publication date	Aug 20, 2024
Grant date	Aug 20, 2024

Abstract

Methods of assessing cytolysis of cancer cells are provided, which include: providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, adding target cells characterized as cancer cells to a well of the device adding effector cells to the well to form a test well, where the effector cells are immune cells obtained or derived from a same patient as the target cells; monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the impedance; and determining effectiveness of effector cell killing of the target cells by comparing the impedance or impedance-based curves over time.

First claim

What is claimed is:

1. A method of assessing cytolysis of cancer cells, the method comprising:
a) providing a cell-substrate impedance monitoring device operably connected to an impedance analyzer, wherein the device comprises a well for receiving cells and an electrode array at a base of the well;
b) adding target cells characterized as cancer cells to the well;
c) adding effector cells to the well to form a test well, wherein the effector cells are immune cells obtained or derived from a same patient as the target cells;
d) monitoring cell-substrate impedance of the test well before and after adding the effector cells and optionally deriving an impedance-based parameter from the cell-substrate impedance; and
e) determining effectiveness of effector cell killing of the target cells by a method selected from the group consisting of:
comparing area under the curve (AUC) of impedance-based curves over time,
performing linear regression analysis of the cell-substrate impedance or impedance-based parameter,
analyzing a killing time 50 (KT50) value, which is determined by calculating time it takes to achieve 50% cytolysis,
analyzing the impedance-based parameter, wherein the impedance-based parameter is a slope for a time period post effector cell addition, and
analyzing a baseline normalized cell index curve for curve kinetics, wherein the baseline normalized cell index curve is plotted by removing a negative control well curve from an impedance-based curve, which is plotted from the cell substrate impedance parameter of the monitored well.

2. The method according to claim 1 , wherein slopes of the impedance-based curves are plotted against each concentration of effector cells being added.

3. The method according to claim 2 , wherein the linear regression analysis is performed by plotting a linear regression.

4. The method according to claim 3 , wherein a slope of the plotted linear regression is determined.

5. The method according to claim 4 , wherein the slope of the plotted linear regression is indicative of potency of the effector cells being added.

6. The method according to claim 5 , wherein the potency of one of the effector cells is compared to the potency of another effector cell by comparing the slopes of linear regression.

7. The method according to claim 1 , wherein the area under the curve (AUC) of the impedance-based curve is calculated upon addition of the effector cells.

8. The method according to claim 7 , wherein an AUC value for each impedance-based curve is plotted against a corresponding concentration of effector cells being added to the device.

9. The method according to claim 1 , wherein duration of monitoring the cell-substrate impedance runs from immediately after adding the effector cells.

10. The method according to claim 9 , wherein a dose-response is calculated for the corresponding effector cells being added to device and is indicative of effector potency.

11. The method according to claim 10 , wherein the dose-response of one type of effector cell is compared to another type of effector cell using a half-maximal effector concentration which results in 50% response (EC-50) value.

12. The method according to claim 1 , wherein the KT50 parameter of target cells is subsequent to adding a given density of effector cells to the wells.

13. The method according to claim 1 , wherein the time it takes (KT) to achieve cytolysis at 10%, 20%, 30%, 40%, 60%, 70%, 80%, 90% and 100% is calculated subsequent to adding a given density or a series of densities of effector cells to the wells containing the target cells.

14. The method according to claim 1 , wherein slope of the impedance-based curve at a given time interval subsequent to adding the effector cells at different densities is determined.

15. The method according to claim 1 , further comprising a step of adding an additional compound suspected of increasing or decreasing effectiveness of effector cell killing of the target cells to the test well and comparing results of step 1e) between the absence and presence of the compound to determine a difference in the effectiveness of effector cell killing of the target cells in response to adding the compound.

16. The method of claim 1 , further comprising adding the target cells to a second well of the device designated a control well, adding a negative control compound to the control well, monitoring impedance of the control well and optionally deriving an impedance-based parameter from the impedance of the control well; and performing step 1e) to determine whether adding the compound increases effector cell killing of target cells.

17. The method according to claim 16 , wherein the compound is selected from the group consisting of an antibody or antibody fragment, a modified antibody or antibody fragment, and a peptide.

18. The method according to claim 16 , wherein the additional compound comprises a check point inhibitor, optionally an antibody or antibody fragment against a member selected from the group consisting of PD1, CTLA-4, CD137, OX40, CD27, CD40L, TIM3 on a surface of effector cells or their respective cognate ligand on a surface of target cells.

19. The method according to claim 16 , wherein the compound is a bispecific engager comprising two polypeptides linked together, wherein each of the two polypeptides binds either the effector cells or the target cells thereby joining the effector cells to the target cells.

20. The method according to claim 19 , wherein the bispecific engager binds a T-cell surface moiety, optionally cluster of differentiation 3 (CD3).

Assignees

• Agilent Technologies Inc

Inventors

• Wang Xiaobo
• Abassi Yama A
• Li Nan
• Muir Lincoln
• Xu Xiao

Classifications

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N5/0693

  Tumour cells; Cancer cells · CPC title

• C12N1/38

  Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N1/34 takes precedence) · CPC title

• C12N1/06

  Lysis of microorganisms · CPC title

• G01N33/5047

  Cells of the immune system · CPC title